Exelixis, Inc. (EXEL)
NASDAQ·Healthcare·Biotechnology
$44.88
+0.52%
Mkt Cap $11.92B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 10, 2026 | $596.52M | $598.66M | +0.36% | $0.77 | $0.94 | +22.08% | — | — |
| Q4 2025 Nov 4, 2025 | $590.16M | $597.75M | +1.29% | $0.69 | $0.78 | +13.87% | — | — |
| Q3 2025 Jul 28, 2025 | $594.93M | $568.26M | -4.48% | $0.65 | $0.75 | +15.38% | — | — |
| Q2 2025 May 13, 2025 | $499.60M | $555.45M | +11.18% | $0.36 | $0.62 | +73.14% | — | — |
| Q1 2025 Feb 11, 2025 | $563.21M | $566.75M | +0.63% | $0.51 | $0.55 | +7.84% | — | — |
| Q4 2024 Oct 29, 2024 | $556.58M | $539.54M | -3.06% | $0.35 | $0.40 | +14.29% | — | — |
| Q3 2024 Aug 6, 2024 | $465.00M | $637.18M | +37.03% | $0.30 | $0.77 | +156.67% | — | — |
| Q2 2024 Apr 30, 2024 | $460.62M | $425.23M | -7.68% | $0.28 | $0.17 | -39.29% | — | — |
| Q1 2024 Feb 6, 2024 | $480.17M | $479.65M | -0.11% | $0.21 | $0.27 | +28.57% | — | — |
| Q4 2023 Nov 1, 2023 | $471.89M | $471.92M | +0.01% | $0.10 | $0.10 | +0.00% | — | — |
| Q3 2023 Aug 1, 2023 | $447.63M | $469.85M | +4.96% | $0.16 | $0.25 | +56.25% | — | — |
| Q2 2023 May 9, 2023 | $424.10M | $408.79M | -3.61% | $0.15 | $0.12 | -20.00% | — | — |
| Q1 2023 Feb 7, 2023 | $417.61M | $423.92M | +1.51% | -$0.05 | -$0.03 | +40.00% | — | — |
| Q4 2022 Nov 1, 2022 | $403.47M | $411.74M | +2.05% | $0.19 | $0.23 | +21.05% | — | — |
| Q3 2022 Aug 9, 2022 | $391.03M | $419.43M | +7.26% | $0.19 | $0.22 | +15.79% | — | — |
| Q2 2022 May 10, 2022 | $374.45M | $355.98M | -4.93% | $0.14 | $0.21 | +50.00% | — | — |
| Q1 2022 Feb 17, 2022 | $355.78M | $451.14M | +26.80% | $0.06 | $0.29 | +383.33% | — | — |
| Q4 2021 Nov 2, 2021 | $345.73M | $328.42M | -5.01% | $0.17 | $0.12 | -29.41% | — | — |
| Q3 2021 Aug 5, 2021 | $295.49M | $385.18M | +30.35% | $0.06 | $0.30 | +400.00% | — | — |
| Q2 2021 May 6, 2021 | $263.42M | $270.23M | +2.59% | — | $0.00 | — | — | — |